@article {Collier2022.10.24.513619, author = {Ai-ris Y. Collier and Jessica Miller and Nicole P. Hachmann and Katherine McMahan and Jinyan Liu and Esther Apraku Bondzie and Lydia Gallup and Marjorie Rowe and Eleanor Schonberg and Siline Thai and Julia Barrett and Erica N. Borducchi and Emily Bouffard and Catherine Jacob-Dolan and Camille R. Mazurek and Audrey Mutoni and Olivia Powers and Michaela Sciacca and Nehalee Surve and Haley VanWyk and Cindy Wu and Dan H. Barouch}, title = {Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters}, elocation-id = {2022.10.24.513619}, year = {2022}, doi = {10.1101/2022.10.24.513619}, publisher = {Cold Spring Harbor Laboratory}, abstract = {Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizing antibodies (NAbs). Our data show that BA.5 NAb titers were comparable following monovalent and bivalent mRNA boosters.Competing Interest StatementThe authors have declared no competing interest.}, URL = {https://www.biorxiv.org/content/early/2022/10/25/2022.10.24.513619}, eprint = {https://www.biorxiv.org/content/early/2022/10/25/2022.10.24.513619.full.pdf}, journal = {bioRxiv} }